Metastatic Melanoma Research
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".
Deadline for manuscript submissions: closed (6 October 2023) | Viewed by 269
Special Issue Editors
2. Charles Perkins Centre, The University of Sydney, Sydney, Australia
3. Faculty of Medicine and Health, The University of Sydney, Sydney, Australia
4. Blacktown Hospital, Sydney, Australia
Interests: melanoma; immunotherapy; biomarkers; resistance; immunology
Special Issues, Collections and Topics in MDPI journals
2. Charles Perkins Centre, The University of Sydney, Sydney, Australia
3. Faculty of Medicine and Health, The University of Sydney, Sydney, Australia
Interests: melanoma; immunotherapy; biomarkers; immunology
Special Issue Information
Dear Colleagues,
Melanoma is the most aggressive form of skin cancer due to its ability to spread locally and distantly to other sites at a rapid rate, and it accounts for the majority of skin-cancer-related deaths. Despite recent advances in therapeutics to treat melanoma, the incidence of melanoma is expected to increase by 16% by 2030. It is therefore critical to understand the biology of melanoma and factors associated with a risk of metastases as well as identify biomarkers of response or resistance to currently available therapies. Furthermore, an improved understanding of mechanisms of resistance to the standard-of-care treatment and discovery of new and novel therapies for patients with resistance is key to curing melanoma.
This Special Issue will focus on a wide breadth of research in the field of metastatic melanoma including melanoma biology and pathology, genetics and molecular biology, immunology, biomarkers, management, and treatment (including targeted and immunotherapies) of metastatic melanoma. We invite authors to submit original research (basic science, translational, and clinical research are all encouraged) and review articles focused on these various aspects of metastatic melanoma research.
Dr. Inês Pires da Silva
Dr. Tuba Nur Gide
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- melanoma
- skin cancer
- metastasis
- therapy
- treatment
- immunotherapy
